If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== 1958 === January: Mao Zedong initiates the Great Leap Forward. January 31: The U.S. Army launches Explorer 1, the first American artificial satellite. February 1: The United Arab Republic is formed. March 14: The United States imposes an arms embargo on Cuba. May 18: On a bombing mission in support of the anti-Sukarno Permesta Rebellion, a B-26 bomber supplied by the CIA is shot down in Ambon, Indonesia. The pilot, US citizen Allen Lawrence Pope is captured and imprisoned. June: A C-118 transport, hauling freight from Turkey to Iran, is shot down. The nine crew members are released by the Russians little more than a week later. July 14: A coup in Iraq, the 14 July Revolution, removes the pro-British monarch. Iraq begins to receive support from the Soviets. Iraq will maintain close ties with the Soviets throughout the Cold War. July 15: A political crisis occurred in Lebanon. July 29: NASA was founded. August: Thor IRBM deployed to the UK, within striking distance of Moscow. August 23: Second Taiwan Strait Crisis begins when China begins to bomb Quemoy. September 1: Iceland expands its fishing zone. United Kingdom opposed the action and eventually deploy some of its navy to the zone, thus triggering the Cod Wars. October 8: Guinea becomes independent from France. October 11: Pioneer 1 was launched. November 8: Pioneer 2 was launched. November 10: Start of the 1958–1959 Berlin crisis, Nikita Khrushchev asks the West to leave Berlin. December 6: Pioneer 3 was launched.
There are approximately 300 types of garlic produced worldwide. Garlic market regions include North America, Europe and Asia-Pacific. Within China, which produces the largest amounts of garlic, there are five main provinces in which garlic is grown, including Shandong, Henan, Jiangsu, Yunnan and Hebei. As soft neck varieties tend to flourish in warmer climates where winters are mild, the Chinese provinces are suitable for harvesting and manufacturing garlic powder.
=== Blood supply === The pancreas has a rich blood supply, with vessels originating as branches of both the coeliac artery and superior mesenteric artery. The splenic artery, the largest branch of the celiac trunk, runs along the top of the pancreas and supplies the left part of the body and the tail of the pancreas through its pancreatic branches, the largest of which is called the greater pancreatic artery. The superior and inferior pancreaticoduodenal arteries run along the back and front surfaces of the head of the pancreas adjacent to the duodenum. These supply the head of the pancreas. These vessels join together (anastomose) in the middle. The body and neck of the pancreas drain into the splenic vein, which sits behind the pancreas. The head drains into, and wraps around, the superior mesenteric and portal veins, via the pancreaticoduodenal veins. The pancreas drains into lymphatic vessels that travel alongside its arteries, and it has a rich lymphatic supply. The lymphatic vessels of the body and tail drain into splenic lymph nodes, and eventually into lymph nodes that lie in front of the aorta, between the coeliac and superior mesenteric arteries. The lymphatic vessels of the head and neck drain into intermediate lymphatic vessels around the pancreaticoduodenal, mesenteric and hepatic arteries, and from there into the lymph nodes that lie in front of the aorta.
== Description == The neon tetra has a light-blue back over a silver-white abdomen. The fish is characterized by a bright iridescent blue horizontal stripe along each side of the fish from its nose to the base of the adipose fin, and an iridescent red stripe that begins at the middle of the body and extends posteriorly to the base of the caudal fin. The fish is partially transparent (including fins) except for these markings. Sexual dimorphism is slight, with the female having a slightly larger belly, and a bent iridescent stripe rather than the male's straight stripe. During the night, the blue and red become gray or black as the fish rests. It reactivates once it becomes active in the morning. This peculiar change is due to the neon tetras capacity to change the color of its iridescent stripe in response to lighting conditions. In a light-adapted state it is blue-green, likewise in a dark-adapted state its color changes to indigo. This change is produced by guanine crystals in their cells that reflect light. The neon tetra grows to approximately 4 cm (1.6 in) in overall length.
Sources: en.wikipedia.org
At a meeting of the Pheu Thai Party on 20 March 2022, Paetongtarn was elected as "Head of the Pheu Thai Family". When speaking at the Pheu Thai Party's annual general meeting in April 2022, she said that she wanted to see regime change in Thailand and wanted to gain more experience before standing for the post of the country's prime minister. Paetongtarn became the leading prime minister-candidate in the opinion polls. In April 2023, she was officially nominated as one of the three prime minister-candidates of Pheu Thai Party for the general election, along with Srettha Thavisin and Chaikasem Nitisiri. After the general election in May 2023, the Pheu Thai Party secured the second-highest number of seats in the House of Representatives, following the Move Forward Party. She expressed disappointment that the party did not achieve first place as planned but stated that she was ready to work with the Move Forward Party and other parties willing to form a coalition with both parties. However, after Pheu Thai Party withdrew from the memorandum of understanding to form a government with the Move Forward Party, on 9 August, she and Pheu Thai Party executives walked from the OAI Tower, where the party's headquarters are located, to the neighbouring Thai Summit Tower to discuss with the Move Forward Party leaders about endorsing a candidate for the third round of prime ministerial voting.
4-Fluoro-7-nitrobenzofurazan (NBD-F) is a fluorogenic, amine labeling dye that is not fluorescent itself, but covalently reacts with secondary or primary amines to form a fluorescently labeled product. It and other fluorogenic benzofurans (i.e. NBD-Cl) are used for derivitization in HPLC applications. After the fluorogenic reaction, it can be detected with an excitation wavelength of 470 nm (blue) and an emission wavelength of 530 nm (green), enabling an HPLC limit of detection of 10 fmol.
== Prognosis == The prognosis for individuals with severe LNS is poor. Death is usually due to kidney failure or complications from hypotonia, in the first or second decade of life. Less severe forms have better prognosis.
Sources: en.wikipedia.org
Polypyrrole (PPy) is an organic polymer obtained by oxidative polymerization of pyrrole. It is a solid with the formula H(C4H2NH)nH. It is an intrinsically conducting polymer, used in electronics, optical, biological and medical fields.
Guo Li Zhuang is a Chinese cuisine restaurant that specializes in penis dishes. The restaurant features table-side traditional Chinese medicine nutritionists that recommend dishes based on diners' ailments; penises offered include dog, goat, deer, bull, ox, yak, sheep, horse, donkey, and seal. The restaurant has expanded from America to China, with multiple locations in the Beijing area.
MPEG LA is making claims that DisplayPort implementation requires a license and a royalty payment. It is important to note that these are only CLAIMS. Whether these CLAIMS are relevant will likely be decided in a US court. By March 2017, that statement had been removed from the official FAQ, while the various other references to being royalty-free were kept. By November 2018, mentions of DisplayPort being royalty-free were removed from the FAQ. While VESA does not charge any per-device royalty fees, VESA requires membership for access to said standards. The minimum cost is presently $5,000 (or $10,000 depending on Annual Corporate Sales Revenue) annually.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.